Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects

Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of moto...

Full description

Saved in:
Bibliographic Details
Published inEuropean archives of psychiatry and clinical neuroscience Vol. 259; no. 5; p. 284
Main Authors Roser, Patrik, Gallinat, Jürgen, Weinberg, Gordon, Juckel, Georg, Gorynia, Inge, Stadelmann, Andreas M
Format Journal Article
LanguageEnglish
Published Germany 01.08.2009
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum.
AbstractList Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum.Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum.
Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central cannabinoid (CB(1)) receptors in the basal ganglia, the cerebral cortex and the cerebellum indicate their implication in the regulation of motor activity. Based on the close relationship between cannabis use, the endogenous cannabinoid system and motor disturbances found in schizophrenia, we expected that administration of cannabinoids may change pattern of psychomotor activity like in schizophrenic patients. This prospective, double-blind, placebo-controlled cross-over study investigated the acute effects of cannabinoids on psychomotor performance in 24 healthy right-handed volunteers (age 27.9 +/- 2.9 years, 12 male) by comparing Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and standardized cannabis extract containing Delta(9)-THC and cannabidiol. Psychomotor performance was assessed by using a finger tapping test series. Cannabis extract, but not Delta(9)-THC, revealed a significant reduction of right-hand tapping frequencies that was also found in schizophrenia. As to the pure Delta(9)-THC condition, left-hand tapping frequencies were correlated with the plasma concentrations of the Delta(9)-THC metabolite 11-OH-THC. These effects are thought to be related to cannabinoid actions on CB(1) receptors in the basal ganglia, the cerebral cortex and the cerebellum. Our data further demonstrate that acute CB(1) receptor activation under the cannabis extract condition may also affect intermanual coordination (IMC) as an index of interhemispheric transfer. AIR-Scale scores as a measure of subjective perception of intoxication were dose-dependently related to IMC which was shown by an inverted U-curve. This result may be due to functional changes involving GABAergic and glutamatergic neurotransmission within the corpus callosum.
Author Gorynia, Inge
Roser, Patrik
Gallinat, Jürgen
Weinberg, Gordon
Stadelmann, Andreas M
Juckel, Georg
Author_xml – sequence: 1
  givenname: Patrik
  surname: Roser
  fullname: Roser, Patrik
  email: patrik.roser@rub.de
  organization: Department of Psychiatry, Ruhr-University Bochum, Bochum, Germany. patrik.roser@rub.de
– sequence: 2
  givenname: Jürgen
  surname: Gallinat
  fullname: Gallinat, Jürgen
– sequence: 3
  givenname: Gordon
  surname: Weinberg
  fullname: Weinberg, Gordon
– sequence: 4
  givenname: Georg
  surname: Juckel
  fullname: Juckel, Georg
– sequence: 5
  givenname: Inge
  surname: Gorynia
  fullname: Gorynia, Inge
– sequence: 6
  givenname: Andreas M
  surname: Stadelmann
  fullname: Stadelmann, Andreas M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19224107$$D View this record in MEDLINE/PubMed
BookMark eNpNkE1LxDAQhoOsuOvqD_AiOXmrTpp-HmX9hAU97L2kzYRmaZOapGD9K_5ZK7uCl5nhfR_mZeacLIw1SMgVg1sGkN95gASyCKCMoMiKKD0hK5ZwHhVJyRb_5iU5934PACyN4YwsWRnHCYN8Rb7f_dS0trfBOjqgU9b1wjRItaEOOxG0NTRYKpoxILVOdFTIXhvtgzuYVtEH7IIoo4Cz1k7S2UYYI2pt7EwbSX2Yq3BSf6GkR89T_JzxJvwmtSi60E60Hedw6sd6j03wF-RUic7j5bGvye7pcbd5ibZvz6-b-200pEkelTLleS0hUzwGyWSSchQFxHHJIZYKBatVzmJWqkzN1zPFZCqB17KWKPI84Wtyc1g7OPsxog9Vr32DXScM2tFXWc4KBgxm8PoIjnWPshqc7oWbqr9v8h_gEX1p
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1007/s00406-009-0868-5
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1433-8491
ExternalDocumentID 19224107
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-Y2
.86
.GJ
.VR
06C
06D
0R~
0VY
1N0
2.D
203
28-
29G
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3O-
4.4
406
408
409
40D
40E
53G
5GY
5QI
5RE
5VS
67Z
6NX
7X7
88E
8AO
8FI
8FJ
8UJ
95-
95.
95~
96X
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AAPKM
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBRH
ABBXA
ABDBE
ABDBF
ABDZT
ABECU
ABFSG
ABFTV
ABHLI
ABHQN
ABIPD
ABIVO
ABJNI
ABJOX
ABKCH
ABKTR
ABLJU
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABRTQ
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACSTC
ACUDM
ACUHS
ACZOJ
ADBBV
ADHIR
ADHKG
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFEXP
AFFNX
AFHIU
AFKRA
AFLOW
AFOHR
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGQPQ
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AIXLP
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AOCGG
ARMRJ
ATHPR
AXYYD
AYFIA
AZFZN
AZQEC
B-.
B0M
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
CAG
CCPQU
CGR
COF
CS3
CSCUP
CUY
CVF
DDRTE
DL5
DNIVK
DPUIP
DU5
DWQXO
EAD
EAP
EBC
EBD
EBLON
EBS
ECM
EIF
EIOEI
EJD
EMB
EMK
EMOBN
EN4
EPL
EPS
ESBYG
ESX
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
IAO
IHE
IHR
IJ-
IKXTQ
IMOTQ
IPY
ITC
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LLZTM
M1P
M2M
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPM
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P9S
PF0
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PSYQQ
PT4
PT5
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNI
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
TUS
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
ZMTXR
ZOVNA
ZXP
~8M
~EX
7X8
ID FETCH-LOGICAL-p547-9d537bd06f320d1d453ea80229302dfea1bf71219f6f5201f1d5d03bdbdea7743
ISSN 1433-8491
IngestDate Mon Jul 21 10:56:51 EDT 2025
Mon Jul 21 05:31:43 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p547-9d537bd06f320d1d453ea80229302dfea1bf71219f6f5201f1d5d03bdbdea7743
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
PMID 19224107
PQID 67181010
PQPubID 23479
ParticipantIDs proquest_miscellaneous_67181010
pubmed_primary_19224107
PublicationCentury 2000
PublicationDate 2009-Aug
20090801
PublicationDateYYYYMMDD 2009-08-01
PublicationDate_xml – month: 08
  year: 2009
  text: 2009-Aug
PublicationDecade 2000
PublicationPlace Germany
PublicationPlace_xml – name: Germany
PublicationTitle European archives of psychiatry and clinical neuroscience
PublicationTitleAlternate Eur Arch Psychiatry Clin Neurosci
PublicationYear 2009
References 10729368 - Eur J Pharmacol. 2000 Mar 17;391(3):269-74
10462071 - Life Sci. 1999;65(6-7):703-13
2346396 - Arch Neurol. 1990 Jun;47(6):681-4
18985298 - Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:66-70
5146491 - Neuropsychologia. 1971 Mar;9(1):97-113
10501554 - Neuroreport. 1999 Jun 3;10 (8):1665-9
11176943 - Arch Neurol. 2001 Jan;58(1):105-11
11311783 - Neuroscience. 2001;103(1):9-15
15111259 - Neurotox Res. 2001 Jan;3(1):23-35
10484943 - Am J Psychiatry. 1999 Sep;156(9):1342-8
12664316 - Eur Arch Psychiatry Clin Neurosci. 2003 Feb;253(1):53-9
2308954 - Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
12412831 - J Clin Pharmacol. 2002 Nov;42(11 Suppl):11S-19S
11606325 - Br J Pharmacol. 2001 Oct;134(4):845-52
7918699 - Eur Arch Psychiatry Clin Neurosci. 1994;244(1):33-8
2185537 - Schizophr Bull. 1990;16(1):87-95
9778318 - Chem Res Toxicol. 1998 Oct;11(10 ):1209-16
14751433 - Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60
11157424 - Br J Psychiatry. 2001 Feb;178:116-22
4069913 - Percept Mot Skills. 1985 Oct;61(2):479-95
10529019 - Drug Alcohol Depend. 1999 Oct 1;56(3):167-79
3404162 - J Neurol Neurosurg Psychiatry. 1988 May;51(5):626-9
20218784 - World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):208-19
3732341 - Eur Arch Psychiatry Neurol Sci. 1986;235(5):301-8
8194190 - Clin Electroencephalogr. 1994 Apr;25(2):63-75
7738554 - J Neurol Neurosurg Psychiatry. 1995 Apr;58(4):457-61
11408610 - Mol Pharmacol. 2001 Jul;60(1):155-63
6878516 - Psychol Med. 1983 May;13(2):299-306
10397414 - Psychiatry Res. 1999 May 31;86(2):113-29
10689030 - Neuropsychologia. 2000;38(5):529-34
16306858 - Ther Drug Monit. 2005 Dec;27(6):799-810
8748466 - Psychiatry Res. 1995 Nov 10;61(4):209-29
16266285 - Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):507-30
7840351 - Am J Psychiatry. 1995 Feb;152(2):191-6
7840889 - Behav Brain Res. 1994 Oct 20;64(1-2):229-40
14324315 - J Am Chem Soc. 1965 Jul 20;87:3273-5
9974180 - Neurobiol Dis. 1998 Dec;5(6 Pt B):483-501
7921721 - Br J Psychiatry. 1994 May;164(5):679-81
18544469 - Eur Neuropsychopharmacol. 2008 Aug;18(8):569-77
10728893 - Cortex. 2000 Feb;36(1):1-18
9130308 - Pharmacol Biochem Behav. 1997 Apr;56(4):803-7
7378515 - Biol Psychiatry. 1980 Jun;15(3):381-8
17884351 - Schizophr Res. 2007 Dec;97(1-3):109-17
17828291 - Br J Pharmacol. 2008 Jan;153(2):199-215
2892048 - Lancet. 1987 Dec 26;2(8574):1483-6
9559936 - Neuroreport. 1998 Mar 9;9(4):671-5
16211466 - Neuropsychol Rev. 2005 Jun;15(2):59-71
2914152 - Biol Psychiatry. 1989 Feb 1;25(3):275-84
17876302 - Br J Pharmacol. 2007 Dec;152(7):1092-101
6948308 - Psychiatry Res. 1981 Dec;5(3):247-55
17349865 - Int Rev Neurobiol. 2007;78:289-326
17131214 - Eur Arch Psychiatry Clin Neurosci. 2007 Jun;257(4):203-10
2165569 - Nature. 1990 Aug 9;346(6284):561-4
12764049 - Brain. 2003 Jun;126(Pt 6):1252-70
10771342 - Neuroscience. 2000;97(1):89-97
1390954 - Eur Arch Psychiatry Clin Neurosci. 1992;242(1):39-45
2608767 - Psychiatry Res. 1989 Sep;29(3):247-53
2669836 - Behav Brain Res. 1989 Aug 1;34(1-2):1-33
References_xml – reference: 10529019 - Drug Alcohol Depend. 1999 Oct 1;56(3):167-79
– reference: 11311783 - Neuroscience. 2001;103(1):9-15
– reference: 2608767 - Psychiatry Res. 1989 Sep;29(3):247-53
– reference: 6948308 - Psychiatry Res. 1981 Dec;5(3):247-55
– reference: 18544469 - Eur Neuropsychopharmacol. 2008 Aug;18(8):569-77
– reference: 2669836 - Behav Brain Res. 1989 Aug 1;34(1-2):1-33
– reference: 3732341 - Eur Arch Psychiatry Neurol Sci. 1986;235(5):301-8
– reference: 15111259 - Neurotox Res. 2001 Jan;3(1):23-35
– reference: 17884351 - Schizophr Res. 2007 Dec;97(1-3):109-17
– reference: 16211466 - Neuropsychol Rev. 2005 Jun;15(2):59-71
– reference: 4069913 - Percept Mot Skills. 1985 Oct;61(2):479-95
– reference: 11176943 - Arch Neurol. 2001 Jan;58(1):105-11
– reference: 3404162 - J Neurol Neurosurg Psychiatry. 1988 May;51(5):626-9
– reference: 17349865 - Int Rev Neurobiol. 2007;78:289-326
– reference: 2185537 - Schizophr Bull. 1990;16(1):87-95
– reference: 2914152 - Biol Psychiatry. 1989 Feb 1;25(3):275-84
– reference: 14324315 - J Am Chem Soc. 1965 Jul 20;87:3273-5
– reference: 10728893 - Cortex. 2000 Feb;36(1):1-18
– reference: 2165569 - Nature. 1990 Aug 9;346(6284):561-4
– reference: 7918699 - Eur Arch Psychiatry Clin Neurosci. 1994;244(1):33-8
– reference: 9130308 - Pharmacol Biochem Behav. 1997 Apr;56(4):803-7
– reference: 12412831 - J Clin Pharmacol. 2002 Nov;42(11 Suppl):11S-19S
– reference: 10729368 - Eur J Pharmacol. 2000 Mar 17;391(3):269-74
– reference: 9778318 - Chem Res Toxicol. 1998 Oct;11(10 ):1209-16
– reference: 7840889 - Behav Brain Res. 1994 Oct 20;64(1-2):229-40
– reference: 17828291 - Br J Pharmacol. 2008 Jan;153(2):199-215
– reference: 10771342 - Neuroscience. 2000;97(1):89-97
– reference: 7840351 - Am J Psychiatry. 1995 Feb;152(2):191-6
– reference: 12764049 - Brain. 2003 Jun;126(Pt 6):1252-70
– reference: 9974180 - Neurobiol Dis. 1998 Dec;5(6 Pt B):483-501
– reference: 1390954 - Eur Arch Psychiatry Clin Neurosci. 1992;242(1):39-45
– reference: 10484943 - Am J Psychiatry. 1999 Sep;156(9):1342-8
– reference: 7921721 - Br J Psychiatry. 1994 May;164(5):679-81
– reference: 10462071 - Life Sci. 1999;65(6-7):703-13
– reference: 16306858 - Ther Drug Monit. 2005 Dec;27(6):799-810
– reference: 10501554 - Neuroreport. 1999 Jun 3;10 (8):1665-9
– reference: 11157424 - Br J Psychiatry. 2001 Feb;178:116-22
– reference: 17876302 - Br J Pharmacol. 2007 Dec;152(7):1092-101
– reference: 10689030 - Neuropsychologia. 2000;38(5):529-34
– reference: 12664316 - Eur Arch Psychiatry Clin Neurosci. 2003 Feb;253(1):53-9
– reference: 7378515 - Biol Psychiatry. 1980 Jun;15(3):381-8
– reference: 18985298 - Eur Arch Psychiatry Clin Neurosci. 2008 Nov;258 Suppl 5:66-70
– reference: 9559936 - Neuroreport. 1998 Mar 9;9(4):671-5
– reference: 10397414 - Psychiatry Res. 1999 May 31;86(2):113-29
– reference: 8194190 - Clin Electroencephalogr. 1994 Apr;25(2):63-75
– reference: 20218784 - World J Biol Psychiatry. 2010 Mar;11(2 Pt 2):208-19
– reference: 11606325 - Br J Pharmacol. 2001 Oct;134(4):845-52
– reference: 8748466 - Psychiatry Res. 1995 Nov 10;61(4):209-29
– reference: 2308954 - Proc Natl Acad Sci U S A. 1990 Mar;87(5):1932-6
– reference: 17131214 - Eur Arch Psychiatry Clin Neurosci. 2007 Jun;257(4):203-10
– reference: 7738554 - J Neurol Neurosurg Psychiatry. 1995 Apr;58(4):457-61
– reference: 6878516 - Psychol Med. 1983 May;13(2):299-306
– reference: 16266285 - Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):507-30
– reference: 5146491 - Neuropsychologia. 1971 Mar;9(1):97-113
– reference: 14751433 - Prog Neuropsychopharmacol Biol Psychiatry. 2004 Mar;28(2):355-60
– reference: 2892048 - Lancet. 1987 Dec 26;2(8574):1483-6
– reference: 2346396 - Arch Neurol. 1990 Jun;47(6):681-4
– reference: 11408610 - Mol Pharmacol. 2001 Jul;60(1):155-63
SSID ssj0001520
Score 1.8635563
Snippet Abnormalities in psychomotor performance are a consistent finding in schizophrenic patients as well as in chronic cannabis users. The high levels of central...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 284
SubjectTerms Administration, Oral
Adult
Analysis of Variance
Cannabidiol - administration & dosage
Cannabidiol - pharmacology
Cannabinoids - administration & dosage
Cannabinoids - pharmacology
Cannabis - chemistry
Cross-Over Studies
Double-Blind Method
Dronabinol - administration & dosage
Dronabinol - analogs & derivatives
Dronabinol - blood
Dronabinol - metabolism
Dronabinol - pharmacology
Female
Fingers - physiology
Functional Laterality - drug effects
Humans
Male
Neuropsychological Tests
Plant Preparations - chemistry
Plant Structures - chemistry
Psychomotor Performance - drug effects
Reference Values
Title Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects
URI https://www.ncbi.nlm.nih.gov/pubmed/19224107
https://www.proquest.com/docview/67181010
Volume 259
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBbb5NJLaekraZvq0FtQsC3bio9NukkI6bYUB_ZmJEumC8EOu95D8lf6d_rDOmNZspdunxezaNmV0XzMQzPfDCHveCBB7euSHYdCslhnhmUiUgycDRUYQIjoGHIfZ-nFdXw5T-aTyfdR1dK6VUfl_VZeyf9IFdZArsiS_QfJ-j-FBfgM8oUnSBiefyVjq73gsJsl9h_2DADPUcFMQHMoy64YAKn4cqNXLnqKH8xNKzPWGlj7eqfBnsm6lhAvN7aJgLtrWNyDa9p_tzoElY70KtzJMinv-ml_q7XCm53V1ht_OWpzO5RZW2qdY2iOGmx6zOH4x6UfKOC5RecSG4pLm03BjP_JKVJJh2TTwlevnUOMPRQcXGIxyY1PCWzcfGS-7s4p65hzdhzbaV9HZstar-Gjvun4YpxEt_razqf7yY7Y0hHsNIsXLt3WyFAbjKYrFJh9Ks6ur66KfDrPH5DdCIIV1LZi7sN-8Le65qD-zVxuPbCtbDc2-HWc0_k7-WPyqA9U6HuLuidkYuqn5NsIcXSEOLqoqUMcbRvaIY4i4ugm4mhT0d8gjgIU6Bhx1CGO9ojDnXrE0Q5x1CHuGcnPpvnpBevHe7DbJBYs0wkXSgdpxaNAhzpOuJFI_M54EOnKyFBVIgSDWqUVnGBYhTrRAVdaaSMhaOHPyU7d1OYloTFY9DAEjSPKCvyrRIKbqo1SaRka8IjFHnnrTrUA7YkpMVmbZr0qUnDNwCgFe-SFPezi1jZ5KSDyAec2EPt__O0r8nBA52uy0y7X5g14qq066IBwQHZPprPPX34AwOOhCQ
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Psychomotor+performance+in+relation+to+acute+oral+administration+of+Delta9-tetrahydrocannabinol+and+standardized+cannabis+extract+in+healthy+human+subjects&rft.jtitle=European+archives+of+psychiatry+and+clinical+neuroscience&rft.au=Roser%2C+Patrik&rft.au=Gallinat%2C+J%C3%BCrgen&rft.au=Weinberg%2C+Gordon&rft.au=Juckel%2C+Georg&rft.date=2009-08-01&rft.issn=1433-8491&rft.eissn=1433-8491&rft.volume=259&rft.issue=5&rft.spage=284&rft_id=info:doi/10.1007%2Fs00406-009-0868-5&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1433-8491&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1433-8491&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1433-8491&client=summon